Related Experiment Video

Updated: Sep 28, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

[Current perspectives in the treatment of Huntington's chorea]

Włodzimierz Kuran

    Neurologia I Neurochirurgia Polska
    |November 7, 2002
    PubMed

    Insights

    Huntington's chorea is a genetic neurodegenerative disease caused by a mutation in the huntingtin gene. Current treatments focus on managing symptoms and exploring neuroprotective strategies for future therapeutic options.

    Area of Science:

    • Neuroscience
    • Genetics
    • Pharmacology

    Context:

    • Huntington's chorea (HD) is an autosomal dominant, progressive neurodegenerative disorder.
    • The genetic basis involves a dynamic mutation in the ITI5 gene on chromosome 4p16.3, encoding the huntingtin protein.
    • Currently, no effective cure exists, and treatment focuses on symptom management.

    Purpose:

    • To review current treatment modalities for Huntington's chorea.
    • To highlight the potential of neuroprotective therapies for future Huntington's disease management.

    Summary:

    • Huntington's chorea results from a known genetic defect, a dynamic mutation in the ITI5 gene.
    • The disease progresses, leading to a fatal outcome, with no definitive cure identified.
    • Treatment strategies discussed emphasize managing various disturbances, with a focus on neuroprotection.

    Impact:

    • Provides an overview of therapeutic approaches for Huntington's chorea.
    • Suggests that neuroprotective methods may offer improved outcomes in the future.
    • Aids clinicians and researchers in understanding current and potential future treatments for this genetic neurological disorder.

    More Related Videos

    Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function11:47

    Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

    Published on: January 22, 2017

    Related Concept Videos

    Huntington Disease l: Introduction01:21

    Huntington Disease l: Introduction

    Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
    Parkinson's Disease: Treatment01:24

    Parkinson's Disease: Treatment

    Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
    Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
    Parkinson's Disease: Overview01:15

    Parkinson's Disease: Overview

    Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
    Alzheimer's Disease: Treatment01:22

    Alzheimer's Disease: Treatment

    Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
    Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

    Direct-Acting Cholinergic Agonists: Therapeutic Uses

    Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
    Cholinergic Antagonists: Therapeutic Uses01:26

    Cholinergic Antagonists: Therapeutic Uses

    Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
    Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...